OK SB1344

Creates the Insulin Access and Affordability Program administered by the Oklahoma State Department of Health to increase patient access to affordable insulin, boost marketplace competition, and address generic insulin shortages

Directs the Department to provide financial support to a nonprofit pharmaceutical manufacturer developing a fast-acting biosimilar insulin using funds appropriated by the Legislature

Requires a memorandum of understanding (MOU) before any funds are disbursed, with the manufacturer matching state funds with equal non-state funding

MOU must include manufacturer commitment to produce insulin at low net cost without rebates, estimated savings projections, repayment provisions if the manufacturer fails to deliver, and annual progress reports

Effective July 1, 2026, with an emergency clause allowing immediate effect upon passage and approval